Legal

Important Safety Information & Consumer Rights

Effective Date: July 1, 2026
Last Updated: July 1, 2026

Read this important safety information before using any medication. This page provides general safety information about medications that may be prescribed through SurpassMD. It is not a substitute for the advice of your Provider or the information provided with your medication. Always talk to your Provider about the benefits and risks of any treatment, and disclose your complete medical history. If you are experiencing a medical emergency, call 911.

1. Compounded Medications Are Not FDA-Approved

Certain medications offered through the Services are compounded. Compounded medications are prepared by a licensed pharmacy for an individual patient pursuant to a prescription. They are not approved by the FDA, and the FDA does not review compounded medications for safety, effectiveness, or quality before they are marketed. Whether a particular compounded medication may lawfully be dispensed to you depends on the specific pharmacy, your prescription, your individual clinical need, and applicable federal and state compounding requirements, including Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Compounded medications are not generic equivalents of, and have not been determined to be therapeutically equivalent to, any FDA-approved product, and may differ in appearance, strength, or inactive ingredients.

2. Important Safety Information: Compounded Semaglutide

Boxed Warning: Risk of Thyroid C-Cell Tumors

Semaglutide causes thyroid C-cell tumors in rodents. It is not known whether semaglutide causes such tumors, including medullary thyroid carcinoma (MTC), in humans. Semaglutide is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Patients should be counseled regarding the potential risk of MTC and the symptoms of thyroid tumors, such as a mass in the neck, difficulty swallowing, shortness of breath, or persistent hoarseness.

Do not use semaglutide if you

have or have had MTC or MEN 2; are allergic to semaglutide or any of its ingredients; or are pregnant or planning to become pregnant. Semaglutide may cause fetal harm; discontinue use at least two months before a planned pregnancy.

Warnings and precautions

Semaglutide may cause inflammation of the pancreas (pancreatitis), gallbladder problems, low blood sugar (especially when used with insulin or a sulfonylurea), acute kidney injury (often related to dehydration from nausea, vomiting, or diarrhea), serious allergic reactions, and diabetic retinopathy complications. Stop use and seek care for severe abdominal pain or signs of an allergic reaction. Tell your Provider about all medical conditions and medications, including any history of depression or mood changes.

Common side effects

The most common side effects include nausea, vomiting, diarrhea, abdominal pain, constipation, indigestion, and fatigue. This is not a complete list. Report side effects to your Provider and to the FDA at 1-800-FDA-1088.

3. Important Safety Information: Compounded Tirzepatide

Boxed Warning: Risk of Thyroid C-Cell Tumors

Tirzepatide causes thyroid C-cell tumors in rats. It is not known whether tirzepatide causes such tumors, including medullary thyroid carcinoma (MTC), in humans. Tirzepatide is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Patients should be counseled regarding the potential risk of MTC and the symptoms of thyroid tumors, such as a mass in the neck, difficulty swallowing, shortness of breath, or persistent hoarseness.

Do not use tirzepatide if you

have or have had MTC or MEN 2; are allergic to tirzepatide or any of its ingredients; or are pregnant or planning to become pregnant. Tirzepatide may cause fetal harm; discontinue use before a planned pregnancy.

Warnings and precautions

Tirzepatide may cause pancreatitis, gallbladder problems, low blood sugar (especially with insulin or a sulfonylurea), acute kidney injury, serious allergic reactions, and diabetic retinopathy complications. Tirzepatide may also reduce the effectiveness of oral contraceptives; talk to your Provider about switching to a non-oral contraceptive, or adding a barrier method for four weeks after starting tirzepatide and for four weeks after each dose increase. Stop use and seek care for severe abdominal pain or signs of an allergic reaction.

Common side effects

The most common side effects include nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, injection-site reactions, fatigue, and decreased appetite. This is not a complete list. Report side effects to your Provider and to the FDA at 1-800-FDA-1088.

4. Compounded GLP-1 Dosing Safety

Compounded GLP-1 medications can come in different concentrations and presentations, and dosing errors are a known risk that the FDA has warned about. A dose may be written in milligrams (mg) while a syringe is marked in units or milliliters, which can lead to taking far more than intended. To use these medications safely: confirm the concentration and your exact dose with your Provider; never assume two products are dosed the same way; measure carefully and do not change your dose or titration schedule on your own; use only the dosing device you are given or directed to use; and store the medication refrigerated and protected from light and freezing as instructed. If a medication has been left at room temperature too long, frozen, or otherwise exposed to improper temperatures, do not use it and contact us. If you are unsure how to measure or inject a dose, stop and ask your Provider before proceeding.

5. Important Safety Information: Testosterone

Testosterone is used to treat low testosterone (hypogonadism) in men who have a related medical condition. It comes in several forms, including injectable, topical (gel or cream), and oral. Some testosterone products are FDA-approved; testosterone may also be compounded, in which case the compounding disclaimer above applies. Different testosterone products carry different boxed warnings: topical products carry a boxed warning that secondary exposure through skin contact can cause virilization in children and in women, and oral testosterone undecanoate carries a boxed warning that it can increase blood pressure and the risk of heart attack and stroke. Follow the specific instructions and warnings that come with your medication.

Do not use testosterone if you

are a man with breast cancer or known or suspected prostate cancer; are a woman, particularly if you are pregnant, may become pregnant, or are breastfeeding, because testosterone can cause serious harm to a fetus and is not for use in women; or are allergic to testosterone or any ingredient in the product. Testosterone is not approved to improve athletic performance or for low testosterone related only to aging without a diagnosed medical condition.

Warnings and precautions

Testosterone may increase your red blood cell count (polycythemia), which may require monitoring and dose changes; increase the risk of blood clots in the veins, such as deep vein thrombosis and pulmonary embolism; increase blood pressure, which can raise cardiovascular risk, although a large safety trial did not find an increase in major cardiovascular events such as heart attack or stroke when testosterone was used to treat diagnosed hypogonadism; worsen symptoms of an enlarged prostate (benign prostatic hyperplasia) and require monitoring of prostate-specific antigen (PSA); worsen sleep apnea; cause fluid retention, which can be serious for people with heart, kidney, or liver disease; cause breast enlargement (gynecomastia); and reduce sperm production and impair fertility. Testosterone is a Schedule III controlled substance that can be abused and can lead to dependence; do not exceed your prescribed dose. If you use a topical product, wash your hands after applying it, keep the application site covered, and avoid skin-to-skin contact with others, especially women and children, to prevent secondary exposure.

Common side effects

Common side effects may include acne, injection-site or application-site reactions, an increased red blood cell count, fluid retention, mood changes, and changes in sex drive. This is not a complete list. Report side effects to your Provider and to the FDA at 1-800-FDA-1088.

Monitoring

Your Provider may order blood tests before and during treatment, which may include testosterone levels, hematocrit and hemoglobin, and PSA, and may adjust or stop your treatment based on the results.

6. Trademarks and Affiliation

Ozempic® and Wegovy® are registered trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. SurpassMD and the Providers and Pharmacies are not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly, and the compounded medications offered through the Services are not manufactured by them. References to brand-name products are for identification only, and all other trademarks and brand names referenced are the property of their respective owners.

7. Results May Vary

Individual results vary and are not guaranteed. Weight loss depends on many factors, including adherence to your treatment plan, diet, physical activity, and individual health conditions. Any results described on the Services are not typical and should not be expected. SurpassMD does not guarantee any particular outcome.

8. Weight-Loss Consumer Bill of Rights

The following disclosures are provided in accordance with applicable weight-loss consumer protection laws, including Florida Statutes section 501.0575:

Rapid weight loss may cause serious health problems. Rapid weight loss is weight loss of more than 1½ to 2 pounds per week, or weight loss of more than 1 percent of body weight per week.
Consult your personal physician before starting any weight-loss program.
Only permanent lifestyle changes, such as making healthful food choices and increasing physical activity, promote long-term weight loss.
The qualifications of the providers offering this program are available to you upon request.

As a weight-loss consumer, you also have the right to: (a) ask questions about the potential health risks of this program, its nutritional content, and its psychological-support components, and to have those questions answered; (b) receive an itemized statement of the actual or estimated price of the program, including any extra products, services, supplements, examinations, or laboratory tests; (c) know the actual or estimated duration of the program; and (d) know the name, address, and qualifications of the dietitian or nutritionist who reviewed the program.

9. Questions

If you have questions about this information, contact us at support@surpassmd.com, or Life Vitality LLC dba SurpassMD, 16192 Coastal Highway, Lewes, DE 19958. Always consult your Provider with medical questions.